Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Utilising Patient-Reported Experience Measures to Drive Healthcare Improvements: The Application of Validated PREM Survey Tools in a Haemoglobinopathy Network in South London

Blood (2024) 144 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2024-198919

Published: 2024

Journal Articles

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Kenneth W. Wood, PhD, James Geib, BS, Eric Wu, PhD, Jason Berlin, MS, Irena Webster, MPH, MA, Kenneth I. Ataga, MD, Jo Howard, MBBChir, MRCP, FRCPath, Jeremie H. Estepp, MD, Marilyn J. Telen, MD, Julie Brevard, MPH

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-134266

Published: 2020

Journal Articles

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lanetta Bronte-Hall, MD MPH, MSPH, Biree Andemariam, MD, Blyden Gershwin, MD, Sanne Lugthart, MD PhD, Timothy Mant, MB, FFPM, FRCP, Jo Howard, MBBChir, MRCP, FRCPath, Henry Fok, MBBS, PhD, Perla Eleftheriou, FRCPath, MRCP, Robert Ward Hagar, MD, James Mason, DO, Rahul Ballal, PhD, Joelle Lufkin, MPH, Eleanor Lisbon, MD MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140540

Published: 2020

Journal Articles

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Jo Howard, MBBChir, MRCP, FRCPath, Kenneth I. Ataga, MD, R. Clark Brown, MD PhD, Maureen Achebe, MD MPH, Videlis Nduba, MD, Amal El-Beshlawy, MD, Hoda Hassab, MD, Irene Agodoa, MD, Margaret Tonda, PharmD, Sarah Gray, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Elliott Vichinsky, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-140553

Published: 2020

Journal Articles

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Jo Howard, MB, BChir, Elliott Vichinsky, MD UCSF, Jennifer Knight-Madden, MBBS, PhD, Margaret Tonda, PharmD, Carla Washington, Barbara Tong, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Victor R Gordeuk, MD

Blood (2019) 134 (Supplement_1): 1020.

https://doi.org/10.1182/blood-2019-130802

Published: 2019

Journal Articles

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Miguel R. Abboud, MD, Jo Howard, MB, BChir, Rodolfo Cançado, Wally R Smith, MD, Birol Güvenç, MD, Noemi Espurz, Marine Weill, Mariane de Montalembert, MD PhD

Blood (2019) 134 (Supplement_1): 998.

https://doi.org/10.1182/blood-2019-125775

Published: 2019

Journal Articles

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Jo Howard, Claire Jane Hemmaway, Paul Telfer, D. Mark Layton, John Porter, Moji Awogbade, Timothy Mant, Daniel D. Gretler, Kobina Dufu, Athiwat Hutchaleelaha, Mira Patel, Vincent Siu, Sandra Dixon, Noel Landsman, Margaret Tonda, Joshua Lehrer-Graiwer

Blood (2019) 133 (17): 1865–1875.

https://doi.org/10.1182/blood-2018-08-868893

Published: 2019

Journal Articles

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Blood (2018) 132 (Supplement 1): 505.

https://doi.org/10.1182/blood-2018-99-118508

Published: 2018

Journal Articles

How I treat the older adult with sickle cell disease

Swee Lay Thein, Jo Howard

Blood (2018) 132 (17): 1750–1760.

https://doi.org/10.1182/blood-2018-03-818161

Published: 2018

Journal Articles

Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Pain and Quality of Life in Children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b pediatric cohort)

Baba Inusa, MD MRCP, Jo Howard, MBBCh, Subarna Chakravorty, MBBS, PhD FRCPath, MRCP, Maria Pelidis, MD, Swee Lay Thein, DSc,FRCP,FRCPath,MBBS,MRCPath,MRCP, Fenella J Kirkham, MD

Blood (2017) 130 (Supplement 1): 3537.

https://doi.org/10.1182/blood.V130.Suppl_1.3537.3537

Published: 2017

Journal Articles

Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Cognition in children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b paediatric cohort)

April E Slee, Jamie M Kawadler, PhD, Melanie Koelbel, MSc, Hanne Stotesbury, MSc, David C Rees, MD, Maria Pelidis, MD, Jo Howard, MBBCh, Swee Lay Thein, DSc,FRCP,FRCPath,MBBS,MRCPath,MRCP, Simon Skene, PhD, Sahota Sati, BSc, Carol Nwosu, BSc, Maureen Gwam, BSc, Dawn Saunders, MD, Johanna C Gavlak, PhD, Gupta Atul, MD, Simrat Sarkaria, Christina Liossi, PhD, Fenella J Kirkham, MD, Baba Inusa, MD MRCP

Blood (2017) 130 (Supplement 1): 3556.

https://doi.org/10.1182/blood.V130.Suppl_1.3556.3556

Published: 2017

Journal Articles

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study of PF-04447943 in Patients with Stable Sickle Cell Disease: Changes in Exploratory Biomarkers

Robert J Charnigo, MS, Jo Howard, MBBCh, David Beidler, PhD, Denis Rybin, PhD, Beesan Tan, PhD, Alan D Michelson, MD, Andrew L Frelinger, III, PhD, Nicholas Clarke, PhD

Blood (2017) 130 (Supplement 1): 974.

https://doi.org/10.1182/blood.V130.Suppl_1.974.974

Published: 2017

Journal Articles

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Blood (2016) 128 (22): 123.

https://doi.org/10.1182/blood.V128.22.123.123

Published: 2016

Journal Articles

A Genetic Predictive Model for HbF in Sickle Cell Disease

Kate Gardner, MA MBBS MRCP, Tony Fulford, Helen Rooks, Nick Silver, Jo Howard, MB, BChir, Moji Awogbade, Sara Stuart-Smith, Tullie Yeghen, MD BA, BMBS, FRCP, FRCPath, Stephan Menzel, PhD, Swee Lay Thein, MD

Blood (2016) 128 (22): 319.

https://doi.org/10.1182/blood.V128.22.319.319

Published: 2016

Journal Articles

An Ongoing Peer Review Programme for Paediatric and Adult Haemoglobinopathy (HbO) Services in England Drives Improvements in Care

Jo Howard, Josh Wright, MD, Banu Kaya, MD, Subarna Chakravorty, MD PhD, Jane Eminson

Blood (2016) 128 (22): 3526.

https://doi.org/10.1182/blood.V128.22.3526.3526

Published: 2016

Journal Articles

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

Josh Lehrer-Graiwer, MDMPhil, FACC, Jo Howard, MB, BChir, Claire Jane Hemmaway, MD, Moji Awogbade, Paul Telfer, FRCPath,MD, Mark Layton, MB, FRCP, John B. Porter, MD, Timothy Mant, MB, FFPM, FRCP, Kobina Dufu, PhD, Athiwat Hutchaleelaha, PhD, Donna Oksenberg, PhD, Mira Patel, PhD, Margaret Eleanor Tonda, PharmD, Kenneth Bridges, MD, Eleanor Ramos, MD

Blood (2016) 128 (22): 2488.

https://doi.org/10.1182/blood.V128.22.2488.2488

Published: 2016

Journal Articles

Prevention of Morbidity in Sickle Cell Disease (POMS 2): A Pilot Study of Nocturnal Respiratory Support Shows That Auto-Adjusting Positive Airways Pressure Is Safe and Is Preferred to Oxygen Therapy

Jo Howard, MD, Baba Inusa, MD, Christina Liossi, David C. Rees, FRCP, FRCPath, MA, MBBS, Swee Lay Thein, MD DSc, Edith Cheng, Sati Sahota, Nicholas Hart, MD, Patrick Murphy, MD, Johanna Gavlak, Maria Chorozoglou, Eufemia Jacob, PhD RN, Carol Nwosu, Maureen Gwam, SallyAnn Wakeford, Fenella Kirkham, MD

Blood (2015) 126 (23): 993.

https://doi.org/10.1182/blood.V126.23.993.993

Published: 2015

Journal Articles

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Josh Lehrer-Graiwer, MDMPhil, FACC, Jo Howard, MD, Claire Jane Hemmaway, MD, Moji Awogbade, Paul Telfer, FRCPath,MD, Mark Layton, MB, FRCP, Timothy Mant, MB, FFPM, FRCP, Kobina Dufu, PhD, Athiwat Hutchaleelaha, PhD, Teri Koller, MBA, Donna Oksenberg, PhD, Mira Patel, PhD, Eleanor Ramos, MD

Blood (2015) 126 (23): 542.

https://doi.org/10.1182/blood.V126.23.542.542

Published: 2015

Journal Articles

Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis

Eugene Oteng-Ntim, Daveena Meeks, Paul T. Seed, Louise Webster, Jo Howard, Pat Doyle, Lucy C. Chappell

Blood (2015) 125 (21): 3316–3325.

https://doi.org/10.1182/blood-2014-11-607317

Published: 2015

Journal Articles

Safety and Tolerability Of MP4CO: A Dose Escalation Study In Stable Patients With Sickle Cell Disease

Jo Howard, MB, BChir, MRCP, FRCPath, Swee Lay Thein, MBBS, DSc, Frederic Galacteros, MD PhD, Adlette Inati, MD, Marvin Reid, PhD, Peter E. Keipert, PhD, Tania N. Small, MD, Frank Booth, MA MSc BM BCh FACS

Blood (2013) 122 (21): 2205.

https://doi.org/10.1182/blood.V122.21.2205.2205

Published: 2013

NARROW

Utilising Patient-Reported Experience Measures to Drive Healthcare Improvements: The Application of Validated PREM Survey Tools in a Haemoglobinopathy Network in South London

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

How I treat the older adult with sickle cell disease

Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Pain and Quality of Life in Children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b pediatric cohort)

Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Cognition in children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b paediatric cohort)

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study of PF-04447943 in Patients with Stable Sickle Cell Disease: Changes in Exploratory Biomarkers

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

A Genetic Predictive Model for HbF in Sickle Cell Disease

An Ongoing Peer Review Programme for Paediatric and Adult Haemoglobinopathy (HbO) Services in England Drives Improvements in Care

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

Prevention of Morbidity in Sickle Cell Disease (POMS 2): A Pilot Study of Nocturnal Respiratory Support Shows That Auto-Adjusting Positive Airways Pressure Is Safe and Is Preferred to Oxygen Therapy

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis

Safety and Tolerability Of MP4CO: A Dose Escalation Study In Stable Patients With Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only